Physician profile
Katherine Gee
NPI 1891030367
$1,343.43
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $430 · 2023: $387 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.54 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $142.64 | 2021-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $120.44 | 2022-2023 | Qelbree |
| Abbvie INC. | $114.22 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.55 | 2021-2023 | Trintellix |
| Alkermes, INC. | $96.07 | 2022-2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $89.14 | 2021-2024 | Spravato |
| Tris Pharma INC | $81.97 | 2023-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $76.17 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $73.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $62.09 | 2023-2024 | Ingrezza |
| Livanova USA, INC. | $57.48 | 2022 | |
| Adlon Therapeutics L.P. | $38.72 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.32 | 2021 | |
| Lundbeck LLC | $21.61 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $20.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.12 | 2022 | |
| Neos Therapeutics, LP | $18.16 | 2021 | |
| Noven Pharmaceuticals, INC. | $17.04 | 2021 | |
| Eisai INC. | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.